SOHM INC - SHMN STOCK NEWS

SOHM, Inc. (OTC PINK: SHMN) announced an exclusive distribution agreement with Stallion Laboratories Pvt. Ltd. to launch Levetiracetam, a medication for treating epilepsy. Levetiracetam, an FDA-approved anticonvulsant, will be manufactured in Ahmedabad, India, and distributed under SOHM's label. The product is anticipated to generate annual revenues between US$3-5 million, aiming for a 5-10% market share over the coming months. The global antiepileptic drug market is projected to grow at a CAGR of 3.9% from 2021 to 2031, driven by rising epilepsy prevalence. The launch is expected within two months, offering a new treatment option that is particularly beneficial for older adults with dementia.

SOHM, Inc. (OTC PINK:SHMN) announced the launch of its new Topical Skincare line, which includes nine products aimed at treating various dermatological conditions. The company has received orders for two products and five SKUs, with distribution set for retail chains such as Walmart and Publix by late May 2023. CEO Baron Night highlighted the potential for significant revenue growth in the skincare market, projected to reach multi-million dollar sales annually. SOHM also reintroduced an OTC product—a Unisex foam formulation featuring Salicylic Acid for acne and anti-aging. The company aims for organic revenue growth alongside new product pipelines.

SOHM, Inc. (OTC PINK:SHMN) has signed a memorandum of understanding with SRAM & MRAM Group for funding its new pipeline projects. This partnership aims to support the company’s growth initiatives that include manufacturing facilities, a potential acquisition, and new product development aligned with its vision of Globalé Prospéro. The funding is expected to be significant and non-toxic, with SRAM & MRAM having a strong record in project financing, including a $900 million infusion. SOHM anticipates completing its projects swiftly, contingent on government approvals.

SOHM, Inc. (SHMN) has appointed Dr. David Aguilar to its Advisory Board as an Expert Medical Advisor. Dr. Aguilar brings extensive expertise in CMC activities for allogeneic cell-based therapies, pharmacology, genome editing, and regenerative medicine. His track record includes co-founding Exeligen Scientific Inc. and establishing regenerative medicine-focused facilities across North America. President and CEO Baron Night expressed confidence that Dr. Aguilar's experience will enhance SOHM's current and future product pipelines. Further appointments are expected soon.

SOHM, Inc. (OTC PINK:SHMN) announced the expansion of its Advisory Board with the appointment of Wm. Dewey Rushing, a former U.S. FDA investigator, as an expert in Validation and Compliance. This move aims to bolster compliance and regulatory expertise, essential for the company's growth strategy. Mr. Rushing brings over 20 years of experience in pharmaceutical quality validation and cGMP compliance, further strengthening SOHM's commitment to portfolio diversification and expanding its foothold in the healthcare sector.

SOHM, Inc. (OTC PINK:SHMN) has announced a collaboration with J Source Industries to manufacture and distribute Brainwise®, an Omega-3 nutraceutical. This partnership is projected to generate $7,500,000 in revenue over three years, with an initial purchase order of $750,000 already secured. The product aims to enhance cognitive health for children and seniors, addressing conditions like Autism and ADHD. The agreement expands SOHM's market presence into Africa, while also targeting North America and the Middle East, in line with its vision of Globalè Prospèro.

SOHM, Inc. (OTC PINK:SHMN) announced a strategic engagement with Sivana Group to enhance its rebranding and global expansion efforts. This collaboration aims to harness Sivana's industry expertise to develop product portfolios and a long-term growth strategy. Mr. Baron Night, CEO of SOHM, emphasized Sivana's capabilities in brand strategy and business relationships. The partnership aligns with SOHM's vision of 'Globalé Prospéro' and seeks to broaden its reach in the pharmaceutical, nutraceutical, and cosmeceutical sectors globally.

SOHM, Inc. (OTC PINK:SHMN) has announced a strategic acquisition of a Southern California pharmaceutical company, enhancing its manufacturing capabilities under FDA licensing. This acquisition allows SOHM to operate a cGMP-compliant contract manufacturing facility, previously operational since 2000, which currently produces 41,000 gallons of semi-solid, liquid, and topical products annually. The facility can expand to over 160,000 gallons per year, paving the way for increased revenues and profitability. The company aims to leverage this opportunity for growth in OTC, cosmeceuticals, and veterinary markets.